Edition:
United Kingdom

Pernix Therapeutics Holdings Inc (PTX.OQ)

PTX.OQ on NASDAQ Stock Exchange Global Market

0.73USD
22 Oct 2018
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$0.73
Open
$0.75
Day's High
$0.77
Day's Low
$0.70
Volume
11,761
Avg. Vol
21,449
52-wk High
$3.30
52-wk Low
$0.70

Latest Key Developments (Source: Significant Developments)

Pernix No Longer Meets Nasdaq Requirement Of Minimum Market Value Of Publicly Held Shares
Monday, 22 Oct 2018 

Oct 22 (Reuters) - Pernix Therapeutics Holdings Inc ::PERNIX THERAPEUTICS - ON OCT 17 RECEIVED LETTER FROM NASDAQ THAT IT NO LONGER MEETS REQUIREMENT OF MINIMUM MARKET VALUE OF PUBLICLY HELD SHARES.  Full Article

Pernix Therapeutics Holdings’S Subsidiaries File Notice Of Appeal
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Pernix Therapeutics Holdings Inc ::PERNIX THERAPEUTICS HOLDINGS, INC.’S SUBSIDIARIES FILE NOTICE OF APPEAL IN PATENT LITIGATION CONCERNING ZOHYDRO® ER WITH BEADTEK®.PERNIX THERAPEUTICS - DECISION HAS NO IMMEDIATE IMPACT ON CO'S JAN 2018 SETTLEMENT WITH ACTAVIS ON PROPOSED GENERIC VERSION OF ZOHYDRO ER WITH BEADTEK.PERNIX THERAPEUTICS HOLDINGS INC - COURT FOUND ASSERTED CLAIMS OF U.S. PATENT TO BE INFRINGED, BUT INVALID.  Full Article

Agrofresh Names Graham Miao As New CFO
Thursday, 30 Aug 2018 

Aug 30 (Reuters) - AgroFresh Solutions Inc ::AGROFRESH ANNOUNCES CFO CHANGE; NAMES GRAHAM MIAO AS NEW CFO.AGROFRESH SOLUTIONS INC - GRAHAM MIAO WILL BE REPLACING KATHERINE HARPER.AGROFRESH SOLUTIONS INC - MOST RECENTLY, MIAO WAS PRESIDENT AND CFO OF PERNIX THERAPEUTICS HOLDINGS.  Full Article

Pernix Therapeutics Announces Ruling In Patent Litigation
Monday, 27 Aug 2018 

Aug 27 (Reuters) - Pernix Therapeutics Holdings Inc ::PERNIX THERAPEUTICS ANNOUNCES RULING IN PATENT LITIGATION CONCERNING ZOHYDRO ER WITH BEADTEK.PERNIX THERAPEUTICS - IN CO'S LITIGATION AGAINST ALVOGEN MALTA OPERATIONS, COURT FOUND ASSERTED CLAIMS OF U.S. PATENTS TO BE INFRINGED, BUT INVALID.PERNIX THERAPEUTICS - LITIGATION RELATES TO ALVOGEN'S SUBMISSION OF ANDA TO FDA FOR APPROVAL TO MARKET GENERIC VERSION OF CO'S ZOHYDRO ER WITH BEADTEK.PERNIX THERAPEUTICS HOLDINGS INC - INTENDS TO APPEAL INVALIDITY RULING ASPECT OF COURT'S DECISION.  Full Article

Pernix Therapeutics Announces A Series Of Transactions To Strengthen Its Balance Sheet And Improve Financial Flexibility
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Pernix Therapeutics Holdings Inc ::PERNIX THERAPEUTICS ANNOUNCES A SERIES OF TRANSACTIONS TO STRENGTHEN ITS BALANCE SHEET AND IMPROVE FINANCIAL FLEXIBILITY.PERNIX THERAPEUTICS - ENTERED INTO EXCHANGE AGREEMENTS WITH CERTAIN HOLDERS OF PERNIX'S OUTSTANDING 12% SENIOR SECURED NOTES DUE 2020.PERNIX THERAPEUTICS - ALSO ENTERED AMENDMENT TO DELAYED DRAW TERM LOAN FACILITY AMONG A WHOLLY OWNED SUBSIDIARY OF PERNIX AND LENDERS.PERNIX THERAPEUTICS HOLDINGS INC - ALSO ENTERED INTO AMENDMENTS TO ASSET-BASED REVOLVING CREDIT FACILITY AGREEMENT.PERNIX THERAPEUTICS - AMENDMENTS WERE MADE TO PERMIT EXCHANGE OF SENIOR SECURED NOTES INTO COMMON STOCK IN EXCHANGE TRANSACTIONS.PERNIX THERAPEUTICS - AMENDMENTS INCLUDES REDUCTION IN COMMITMENTS UNDER ABL FACILITY FROM $40.0 MILLION TO $32.5 MILLION.  Full Article

Pernix Therapeutics Reports Result Of Bid Process For Acquisition Of Worldwide Rights To Contrave
Friday, 22 Jun 2018 

June 22 (Reuters) - Pernix Therapeutics Holdings Inc ::PERNIX THERAPEUTICS ANNOUNCES RESULT OF BID PROCESS FOR ACQUISITION OF WORLDWIDE RIGHTS TO CONTRAVE® FOR WEIGHT LOSS.NALPROPION PHARMACEUTICALS INFORMED BY OREXIGEN THERAPEUTICS NO OTHER BIDS FOR OREXIGEN'S ASSETS GOT BY COURT-APPROVED BID DEADLINE.NALPROPION ANTICIPATES BEING DECLARED HIGHEST, BEST BIDDER FOR ASSETS AND CLOSING ON DEAL BY JULY 13, 2018.  Full Article

Orexigen Therapeutics Enters Agreement For Sale Of Co
Monday, 23 Apr 2018 

April 23 (Reuters) - Orexigen Therapeutics Inc ::OREXIGEN THERAPEUTICS, INC. ENTERS AGREEMENT FOR SALE OF COMPANY.OREXIGEN THERAPEUTICS INC - ENTERED INTO ASSET PURCHASE DEAL WITH NALPROPION PHARMACEUTICALS, TO SELL SUBSTANTIALLY ALL OF ASSETS OF CO.OREXIGEN THERAPEUTICS INC - WILL SELL WORLD-WIDE RIGHTS TO CONTRAVE /MYSIMBA AND CERTAIN OTHER OREXIGEN ASSETS FOR $75 MILLION IN CASH.OREXIGEN THERAPEUTICS- NALPROPION PHARMACEUTICALS IS A NEWLY FORMED SPECIAL PURPOSE ENTITY CAPITALIZED BY INVESTOR GROUP INCLUDING PERNIX THERAPEUTICS.  Full Article

Pernix Therapeutics Announces Participation In Lead Bid Worldwide Rights Of Contrave
Monday, 23 Apr 2018 

April 23 (Reuters) - Pernix Therapeutics Holdings Inc ::PERNIX THERAPEUTICS ANNOUNCES PARTICIPATION IN LEAD BID FOR ACQUISITION OF WORLDWIDE RIGHTS TO CONTRAVE® FOR WEIGHT LOSS.PERNIX THERAPEUTICS HOLDINGS - TO PARTICIPATE IN INVESTOR GROUP THAT ENTERED INTO "STALKING HORSE" ASSET PURCHASE DEAL TO ACQUIRE SOME ASSETS OF OREXIGEN THERAPEUTICS.PERNIX THERAPEUTICS HOLDINGS - WOULD CONTRIBUTE 10% OF CAPITAL REQUIRED TO FUND PURCHASE PRICE OF DEAL, OR $7.5 MILLION.PERNIX THERAPEUTICS - WOULD CONTRIBUTE 10% OF CAPITAL REQUIRED TO FUND PURCHASE PRICE, OR $7.5 MILLION, FUNDED THROUGH DRAW UNDER EXISTING DELAYED DRAW TERM LOAN FACILITY.  Full Article

Pernix Therapeutics Will Reduce Workforce By 41 Employees
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Pernix Therapeutics Holdings Inc ::PERNIX THERAPEUTICS HOLDINGS INC - WILL REDUCE WORKFORCE BY 41 EMPLOYEES; MAJORITY EXPECTED TO BE WITH CO'S SALES FORCE & COMMERCIAL INFRASTRUCTURE.PERNIX THERAPEUTICS - ‍EXPECTS TO COMPLETE REALIGNMENT PLAN TO REDUCE OPERATING COSTS, ALIGN WORKFORCE ON JAN 5, 2018 - SEC FILING​.  Full Article

Pernix Therapeutics files for mixed shelf offering of up to $150 mln
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Pernix Therapeutics Holdings Inc ::Pernix Therapeutics Holdings files for mixed shelf offering of up to $150 million - SEC filing‍​.  Full Article